Many countries are seeking serology tests to better understand whether people are developing a possible immunity to the novel coronavirus. But reports detailing high rates of false-positive and false-negative results are delaying widespread screening. “These tests are not worth anything, or have very little use,” Schwan said during an early Wednesday conference call regarding the company’s first-quarter earnings, according to Reuters.FierceBiotech
Wednesday, April 22, 2020
COVID-19 antibody testing 'a disaster,' says Roche CEO, as diagnostics sales rise
Many countries are seeking serology tests to better understand whether people are developing a possible immunity to the novel coronavirus. But reports detailing high rates of false-positive and false-negative results are delaying widespread screening. “These tests are not worth anything, or have very little use,” Schwan said during an early Wednesday conference call regarding the company’s first-quarter earnings, according to Reuters.FierceBiotech
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment